Presbyopia drop, Demodex lead recent cornea news

[ad_1]

April 17, 2021

1 min read


We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

The FDA acceptance of an investigational new drug application and an article diving into Demodex led recent cornea/external disease news on Healio/OSN.

Read top-performing cornea coverage below:

FDA accepts IND for presbyopia drop

The FDA has accepted an investigational new drug application for Brimochol, according to a press release from Visus Therapeutics. Read more.

Demodex: Easy to find, not so easy to kill

The Demodex mite, of which there are at least 65 species, is the most common microscopic ectoparasite found on human skin. Demodex folliculorum is responsible for Demodex blepharitis, which accounts for at least 45% of blepharitis cases. Read more.

NOV03 meets primary, secondary endpoints in phase 3 trial

NOV03 met the primary and secondary endpoints in its first phase 3 trial, according to a press release from Bausch + Lomb and Novaliq. Read more.

Prioritizing treatment of underlying inflammation key in dry eye disease

Prioritizing the treatment of underlying inflammation may lead to better outcomes for patients with dry eye disease, according to speakers at the virtual OIS Dry Eye Innovation Showcase. Read more.

Treating dry eye 201: Initiating basic treatment

I frequent a few groups on Facebook and Twitter dedicated to dry eye disease. Not a day goes by without several inquiries about starting to treat DED patients. Read more.

[ad_2]

Source link

Kathy Laura

Leave a Reply

Your email address will not be published.